In a win for AbbVie, a federal appeals court affirmed that AbbVie did not illegally block competition with its 132 patents on Humira, and in a win for brand drug makers, the judges said the size of a patent portfolio is not an indicator of anticompetitive behavior. “[W]hat’s wrong with having lots of patents? If AbbVie made 132 inventions, why can’t it hold 132 patents? The patent laws do not set a cap on the number of patents any one...